Symbiotec Pharmalab
Symbiotec Pharmalab is a specialized pharmaceutical and biotechnology company focused on the manufacture of Corticosteroid and Steroidal Hormone APIs. Operating in the global API sector, the company provides critical ingredients used in the production of various essential medicines.
Price Band
₹938 - ₹988
Lot Size
15 Shares
Issue Size
₹1,757.00 Cr
Fresh Issue
₹150.00 Cr
OFS
₹1,607.00 Cr
Registrar
AI Sentiment Score
Listing Price
₹988.00
vs Issue: ₹988 (0.00%)
📅 IPO Timeline
✓
Open
Aug 24
✓
Close
Aug 27
✓
Allotment
Aug 28
✓
Refund
Aug 31
✓
Demat
Aug 31
✓
Listing
Sep 1
✨ AI Analysis & Prediction
+13.0%
predicted listing gain
The predicted gain is adjusted upward from the 18.72% GMP baseline primarily due to massive QIB subscription (181.2x), which signals strong institutional conviction. While the high OFS component is a slight drag, the company's leadership in the global Corticosteroid API market and consistent revenue growth provide a strong fundamental cushion.
💪 Strengths
- Global leader by volume in Corticosteroid and Steroidal-Hormone APIs
- Presence across top 10 global categories in its niche market
⚠️ Weaknesses
- Low ROE (11.19%) compared to high-growth pharma peers
- High dependence on a specific therapeutic API segment
🚀 Opportunities
- Expansion of global API demand for steroid-based medicines
- Potential for further capacity expansion using IPO funds for debt reduction
🛡️ Threats
- Strict regulatory environment for API manufacturing
- High OFS percentage may signal a lack of promoter confidence in short-term upside
🎯 Objectives of the IPO
| Requirement / Purpose | Amount (₹ Cr) |
|---|---|
| Prepayment and/or repayment, in full or in part, of all or a portion of certain outstanding borrowings availed by the Company | ₹112.50 |
| General corporate purposes | ₹1,644.50 |
📊 Financial Overview
| Metric | FY24 | FY25 | FY26 |
|---|---|---|---|
| Revenue (₹ Cr) | Rs 716.00 Cr | Rs 752.00 Cr | Rs 869.00 Cr |
| Net Profit / PAT (₹ Cr) | Rs 100.00 Cr | Rs 97.00 Cr | Rs 110.00 Cr |
| EBITDA / Op. Profit (₹ Cr) | Rs 172.00 Cr | Rs 203.00 Cr | Rs 239.00 Cr |
| Borrowings (₹ Cr) | Rs 247.00 Cr | Rs 544.00 Cr | Rs 391.00 Cr |
| Total Assets (₹ Cr) | Rs 1,289.00 Cr | Rs 1,580.00 Cr | Rs 1,781.00 Cr |
| ROCE % | 16.00% | 14.00% | 13.00% |
📋 Live Subscription Status
QIB
181.20x
NII
58.01x
Retail
13.69x
Total
75.08x
Updated: Sep 2, 2026 8:03 AM
💼 Reservation Quota
QIB
50.00%
Retail
35.00%
NII
15.00%
📈 Shareholding & Anchor Lock-In
🔗 Important Links & Lead Managers
- Registrar WebsiteVisit →
- Download DRHP ProspectusDownload PDF 📥
- Download RHP ProspectusDownload PDF 📥
Lead Managers / Merchant Bankers
This issue is managed by Hem Securities Ltd., and Share India Capital Services Pvt. Ltd.
Disclaimer: The information provided on this page is for educational and informational purposes only and does not constitute financial advice. IPO investments are subject to market risks. AI-generated analysis is based on publicly available data and may not be accurate. Grey Market Premium (GMP) is unofficial and highly speculative. Always consult a qualified financial advisor and read the DRHP/RHP carefully before making investment decisions.
Symbiotec Pharmalab possesses over 30 years of industry experience, evolving from a small laboratory-scale steroid manufacturer into a fully integrated global enterprise. The company specializes in the complex chemistry of Corticosteroid and Steroidal Hormone Active Pharmaceutical Ingredients (APIs), which serve as the foundation for numerous pharmaceutical formulations.
The company's business model is built on high-barrier technical expertise in steroid chemistry. By maintaining a fully integrated production chain, Symbiotec ensures quality control and cost-efficiency, allowing it to compete effectively on a global scale.
In terms of market position, Symbiotec is a global leader by volume in the production of Corticosteroid and Steroidal-Hormone APIs. As of FY2025, it distinguished itself as the only Indian and global company to have a presence across the top 10 categories within this specific API market.
Operationally, the company maintains a significant footprint with assets growing to ₹1,780.79 crores by 2026. Its leadership is driven by promoters Anil Satwani, Kashish Satwani, Sushil Satwani, and Satwani Holdings LLP, who have steered the company toward global dominance in its niche segment.
The Symbiotec Pharmalab IPO is a Mainboard issue seeking to raise approximately ₹1,757 crores. The offering is structured with a modest fresh issue of ₹150 crores and a significant Offer for Sale (OFS) of approximately 1,62,65,181 equity shares. The price band is set between ₹938 and ₹988 per share, with a minimum lot size of 15 shares. The issue opens on August 24, 2026, closes on August 27, 2026, and is scheduled to list on the BSE and NSE on September 1, 2026.
The proceeds from the fresh issue are primarily earmarked for the prepayment or repayment of outstanding borrowings, amounting to ₹112.50 crores, with the remainder utilized for general corporate purposes. This indicates a focus on deleveraging the balance sheet to improve future financial flexibility.
Financial performance shows a steady upward trajectory. Revenue grew from ₹723.33 crores in FY24 to ₹872.26 crores in FY26. Net Profit (PAT) followed a similar positive trend, increasing from ₹96.79 crores in FY25 to ₹109.90 crores in FY26, reflecting operational efficiency and market demand.
From a valuation perspective, the company reports an EPS of ₹19.10 for FY26. When compared to peers like Divi's Laboratories and Concord Biotech, Symbiotec's niche leadership in steroids provides a competitive edge, though the heavy OFS component suggests significant promoter liquidity events.
Key strengths include its global volume leadership and integrated manufacturing capabilities. However, investors should note the risk associated with the high proportion of OFS, which means the majority of the IPO proceeds go to selling shareholders rather than into company growth. Overall, it presents a stable profile for those seeking exposure to the specialized API sector.